Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | ALPL | P05186 | 1/20 | 0.50 |
| ▸ | ALPI | P09923 | 1/20 | 0.50 |
| ▸ | ALPG | P10696 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL264346 | 0.83 | ALOX15 (0.68) | ALOX15KMT2AMEN1ALPLALPI | |
| SCHEMBL28325138 | 0.81 | ALOX15 (0.65) | ALOX15KMT2AMEN1ALPLALPI | |
| SCHEMBL472034 | 0.81 | ALOX15 (0.65) | ALOX15KMT2AMEN1ALPLALPI | |
| SCHEMBL11562520 | 0.80 | PTGS2 (0.57) | MAPTHPGDSMN1; SMN2L3MBTL1RAB9A | |
| SCHEMBL4960786 | 0.80 | GAA (0.62) | KMT2AMEN1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL4589730 | 0.80 | CYP1A2 (0.54) | ALOX15KMT2AMEN1ALDH1A1NPC1 | |
| SCHEMBL8769150 | 0.80 | ALOX15 (0.59) | ALOX15KMT2AMEN1ALPLALPI | |
| SCHEMBL80061 | 0.80 | ALOX15 (0.59) | ALOX15KMT2AMEN1ALPLALPI | |
| SCHEMBL4645756 | 0.80 | ALOX15 (0.59) | ALOX15KMT2AMEN1ALPLALPI | |
| SCHEMBL25306638 | 0.79 | ALOX15 (0.63) | ALOX15KMT2AMEN1ALPLALPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040220399-A1 | Penicillanic acid derivative compounds and methods of making | RESEARCH CORPORATION TECHNOLOGIES, INC. | 2004-11-04 | — | — | US | claimed |
| US-20030216372-A1 | Inhibitors of serine and metallo-beta-lactamases | ALAMX L.L.C. | 2003-11-20 | — | — | US | claimed |
| WO-2003087105-A1 | INHIBITORS OF SERINE AND METALLO-ß-LACTAMASES | ALAMX, L.L.C. (US) | 2003-10-23 | — | — | WO | claimed |
| EP-1329160-A2 | 4-ACYLAMINOPYRAZOLE DERIVATIVES | Sankyo Company, Limited (JP) | 2003-07-23 | — | — | EP | claimed |
| US-20020198180-A1 | Penicillanic acid derivative compounds and methods of making | RESEARCH CORPORATION TECHNOLOGIES, INC. | 2002-12-26 | — | — | US | claimed |
| US-6436398-B2 | ADMINISTERING A BETA-LACTAM ANTIBIOTIC WITH A BETA-LACTAMASE INHIBITING COMPOUND SUCH AS BENZHYDRYL 2-BETA-(CHLOROACETOXY-METHYL)-6-((Z)-(TERT-BUTOXYCARBONYL)METHYLENE) PENICILLINATE TO TREAT BETA-LACTAM RESISTANT BACTERIAL INFECTIONS | RESEARCH CORPORATION TECHNOLOGIES, INC. | 2002-08-20 | — | — | US | claimed |
| EP-0966471-B1 | 2-BETA-SUBSTITUTED-6-ALKYLIDENE PENICILLANIC ACID DERIVATIVES AS BETA-LACTAMASE INHIBITORS | RES CORP TECHNOLOGIES INC (US) | 2002-06-12 | — | — | EP | claimed |
| US-20010021706-A1 | 2 beta-substituted-6-alkylidene penicillanic acid derivatives as beta-lactamase inhibitors | RESEARCH CORPORATION TECHNOLOGIES, INC. | 2001-09-13 | — | — | US | claimed |
| US-6156745-A | 2β-substituted-6-alkylidene penicillanic acid derivatives as β-lactamase inhibitors | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 2000-12-05 | — | — | US | claimed |
| EP-0966471-A1 | 2-BETA-SUBSTITUTED-6-ALKYLIDENE PENICILLANIC ACID DERIVATIVES AS BETA-LACTAMASE INHIBITORS | Research Corporation Technologies, Inc (US) | 1999-12-29 | — | — | EP | claimed |
| WO-1999033838-A1 | 2-β-SUBSTITUTED-6-ALKYLIDENE PENICILLANIC ACID DERIVATIVES AS β-LACTAMASE INHIBITORS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1999-07-08 | — | — | WO | claimed |
| EP-0089216-A2 | Cephalosporin compounds | GLAXO GROUP LIMITED (GB) | 1983-09-21 | — | — | EP | claimed |
| CN-109831913-B | Reagent for reversibly protecting biomolecules | 生物梅里埃公司 | 2022-01-21 | — | — | CN | disclosed |
| US-20080269247-A1 | Chemokine Inhibiting Piperazine Derivatives and Their Use to Treat Myocarditis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-10-30 | — | — | US | disclosed |
| US-20080119471-A1 | Piperazine urea derivatives for the treatment of endometriosis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-05-22 | — | — | US | disclosed |
| US-7268140-B2 | Piperazine derivatives and their use as anti-inflammatory agents | SCHERING AG (DE) | 2007-09-11 | — | — | US | disclosed |
| WO-1998056771-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-12-17 | — | — | WO | disclosed |
| EP-0089216-A3 | CEPHALOSPORIN COMPOUNDS | GLAXO GROUP LIMITED (GB) | 1984-11-21 | — | — | EP | disclosed |
| EP-0089216-A2 | Cephalosporin compounds | GLAXO GROUP LIMITED (GB) | 1983-09-21 | — | — | EP | disclosed |
| EP-0089216-A2 | Cephalosporin compounds | GLAXO GROUP LIMITED (GB) | 1983-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220399-A1 | Penicillanic acid derivative compounds and methods of making | MRPL21, CYP51A1, RPIA | ALOX15 2019/4885KMT2A 2513/4885MEN1 986/4885 |
| US-20020198180-A1 | Penicillanic acid derivative compounds and methods of making | MRPL21, RPIA, RPN1 | ALOX15 1811/4885KMT2A 2838/4885MEN1 650/4885 |
| US-20080269247-A1 | Chemokine Inhibiting Piperazine Derivatives and Their Use to Treat Myocarditis | CCL2, CCR2, CXCL10 | ALOX15 2360/4885KMT2A 2879/4885MEN1 4643/4885 |
| US-20030216372-A1 | Inhibitors of serine and metallo-beta-lactamases | SRR, BACE1, PRSS1 | ALOX15 2103/4885KMT2A 2245/4885MEN1 211/4885 |
| US-20010021706-A1 | 2 beta-substituted-6-alkylidene penicillanic acid derivatives as beta-lactamase inhibitors | IDUA, NAALAD2, GLA | ALOX15 1579/4885KMT2A 2092/4885MEN1 1792/4885 |
| US-20080119471-A1 | Piperazine urea derivatives for the treatment of endometriosis | ESR2, GPER1, SLC14A1 | ALOX15 2365/4885KMT2A 1364/4885MEN1 3877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.